Medical technology company providing devices, services, and therapies across cardiovascular, surgical, neuroscience, and diabetes care.
Profile & Fundamentals
Medtronic: Company identity, ownership, reported financial performance, balance sheets, and corporate actions.
Profile & Fundamentals
Medtronic Profile & Fundamentals
Examine company identity, ownership, reported performance, valuation, balance-sheet resilience, dividends, buybacks, and material corporate events.
Explore this pageJump to a Profile & Fundamentals section
Explore this research
Profile & Fundamentals contents
Jump directly to any section
Company and Market Context
Company Profile & Ownership
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients in the United States, Ireland, and internationally. It operates through three segments: The Cardiovascular Portfolio, Neuroscience Portfolio, and Medical Surgical Portfolio. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves, left atrial appendage exclusion systems, extracorporeal membrane oxygenation (ECMO) systems and percutaneous coronary intervention products, percutaneous angioplasty balloons, and endovenous products. The Neuroscience Portfolio segment offers medical devices and implants, biologic solutions, spinal cord stimulation and brain modulation systems, implantable drug infusion systems, and interventional products, as well as nerve ablation system under the Accurian name. This segment offers its products for spinal surgeons, neurosurgeons, neurologists, pain management specialists, anesthesiologists, orthopedic surgeons, urologists, urogynecologists, and interventional radiologists, as well as ear, nose, and throat specialists, and energy surgical instruments. The Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure and electrosurgery products, AI-powered surgical video and analytics platform, robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology products, gastrointestinal and hepatologic diagnostics and therapies, and therapies to treat diseases and conditions, and patient monitoring and airway management products, as well as insulin pumps and consumables, continuous glucose monitoring sys
Company profile record
Medtronic PLC
Common Stock · Health Care · Health Care Equipment
Company
- Company / asset
- Medtronic PLC
- Security type
- Common Stock
- Sector
- Health Care
- Industry
- Health Care Equipment
- HQ
- 🇮🇪 Ireland
- Head office
- Building Two, Galway, Ireland, H91 4K49
Leadership & scale
- Chief executive
- Mr. Geoffrey Straub Martha
- CEO year born
- 1970
- Full-time employees
- 95K
- Fiscal year end
- April
- IPO date
- 1978-01-13
Fundamentals snapshot
- Market Cap
- USD 111.9B
- P/E
- 21.4x
- Revenue (Q3 26)
- USD 9.8B
- Profit (Q3 26)
- USD 1.5B
- Dividend Yield
- 2.3%
- Revenue (FY 26)
- USD 36.4B
- Shares in public float
- 1.3B
- Insider ownership
- 0.39%
Reporting & identifiers
- Symbol
- MDT.NYSE
- Listing
- 🇺🇸 United States | Dividend Tax: 30%
- Ticker Currency
- USD
- Income Statement Currency
- USD
- Balance Sheet Currency
- USD
- Cash Flow Currency
- USD
- EPS Currency
- USD
- Contract Type
- SPOT
- ISIN
- IE00BTN1Y115
- Asset ID
- equity_d573891f-97f3-5a8e-8b19-5db704eef9c9
Ownership
Shares Outstanding
Latest: 1.3B | Max: 1.4B | Min: 1.3B
Latest reported ownership snapshot
As of Oct 1, 2026Float Shares
99.34%
1.3B latest reported shares
Insider Ownership
0.39%
Latest reported insider stake
Short Float
0.01%
Latest reported short interest / float
Top Holders
Source tablesView ownership tables
Shares Outstanding
Annual reported shares outstanding; up to 10 reporting dates.
Scroll the table to see every column.
| Reporting date | Shares outstanding |
|---|---|
| 2017-01-01 | 1,365,800,000 |
| 2018-01-01 | 1,360,900,000 |
| 2019-01-01 | 1,351,400,000 |
| 2020-01-01 | 1,352,100,000 |
| 2021-01-01 | 1,355,300,000 |
| 2022-01-01 | 1,332,000,000 |
| 2023-01-01 | 1,331,900,000 |
| 2024-01-01 | 1,286,900,000 |
| 2025-01-01 | 1,287,500,000 |
| 2026-01-01 | 1,285,100,000 |
Top Holders
Available reported ownership records.
Scroll the table to see every column.
| Holder | Shares | Ownership | Reported date |
|---|---|---|---|
| BlackRock Inc | 113,182,567 | 8.85% | 2026-03-31 |
| Vanguard Capital Management, LLC | 83,333,833 | 6.51% | 2026-03-31 |
| State Street Corp | 61,741,014 | 4.83% | 2026-03-31 |
| JPMorgan Chase & Co | 50,973,541 | 3.99% | 2026-03-31 |
| Vanguard MStar Total Stk Mkt Idx Invest | 40,798,416 | 3.19% | 2026-08-31 |
| Vanguard 500 Index Investor | 34,109,699 | 2.67% | 2026-08-31 |
| Vanguard Portfolio Management, LLC | 33,450,558 | 2.62% | 2026-03-31 |
| Geode Capital Management, LLC | 28,736,341 | 2.25% | 2026-03-31 |
| Arnhold & S. Bleichroeder Advisers, LLC | 27,567,966 | 2.16% | 2026-06-30 |
| Bank of America Corp | 26,015,003 | 2.03% | 2026-03-31 |
| Massachusetts Financial Services Company | 21,437,599 | 1.68% | 2026-03-31 |
| Morgan Stanley - Brokerage Accounts | 20,717,029 | 1.62% | 2026-03-31 |
| Deutsche Bank AG | 19,002,414 | 1.49% | 2026-03-31 |
| iShares Core S&P 500 ETF | 17,096,658 | 1.34% | 2026-08-31 |
| Amvescap Plc. | 16,786,998 | 1.31% | 2026-03-31 |
Earnings, Profitability & Valuation
Earnings, Profitability & Valuation
Earnings & Revenue
Earnings and Revenue Trajectory
AI Review
Medtronic's financial results demonstrate an unmistakable shift from multi-year stagnation toward authentic operational acceleration. For fiscal 2026, reported revenue expanded 8.4% to $36.4 billion, and the momentum continued into the first quarter of fiscal 2027 with reported organic growth of 13.7%. While an extra selling week flattered that headline figure, underlying growth remained solid at roughly 7%, spearheaded by an extraordinary 88% surge in cardiac ablation solutions. Crucially, this top-line resurgence is backed by genuine cash generation rather than accounting gimmicks. Trailing free cash flow reached $6.13 billion, comfortably funding $3.64 billion in annual dividend payments while supporting disciplined share buybacks. As high-margin procedural consumables outpace capital equipment sales, earnings quality is steadily improving across core divisions.
Medtronic's financial results demonstrate an unmistakable shift from multi-year stagnation toward authentic operational acceleration. For fiscal 2026, reported revenue expanded 8.4% to $36.4 billion, and the momentum continued into the first quarter of fiscal 2027 with reported organic growth of 13.7%. While an extra selling week flattered that headline figure, underlying growth remained solid at roughly 7%, spearheaded by an extraordinary 88% surge in cardiac ablation solutions. Crucially, this top-line resurgence is backed by genuine cash generation rather than accounting gimmicks. Trailing free cash flow reached $6.13 billion, comfortably funding $3.64 billion in annual dividend payments while supporting disciplined share buybacks. As high-margin procedural consumables outpace capital equipment sales, earnings quality is steadily improving across core divisions.
Revenue, Net Income, and Free Cash Flow
Latest: USD 36.4B | Max: USD 36.4B | Min: USD 3.1B
Valuation
P/E Ratio (TTM)iPublished valuation snapshots use the earnings basis recorded with each observation. Source tables retain that basis.
Latest: 22x
Profitability & Margins
Margins and Operating Efficiency
AI Review
Profitability margins are establishing a durable floor after absorbing years of post-pandemic supply-chain inflation and tariff expenses. Gross margin held steady at 65.0% in fiscal 2026, while operating margin improved to 17.8%. In the first quarter of fiscal 2027, net income jumped 41% as manufacturing efficiencies and favorable procedural mix took hold. This margin recovery reflects structural improvements rather than temporary cost-cutting. Premium pulsed field ablation catheters command higher profitability than older thermal tools, while shedding the lower-margin diabetes division will immediately lift consolidated margins. As automated factory production expands, operating margins possess a clear pathway toward 20% over the next several years.
Profitability margins are establishing a durable floor after absorbing years of post-pandemic supply-chain inflation and tariff expenses. Gross margin held steady at 65.0% in fiscal 2026, while operating margin improved to 17.8%. In the first quarter of fiscal 2027, net income jumped 41% as manufacturing efficiencies and favorable procedural mix took hold. This margin recovery reflects structural improvements rather than temporary cost-cutting. Premium pulsed field ablation catheters command higher profitability than older thermal tools, while shedding the lower-margin diabetes division will immediately lift consolidated margins. As automated factory production expands, operating margins possess a clear pathway toward 20% over the next several years.
Profitability Margins
Latest: 65.0% | Max: 70.0% | Min: 10.4%
Latest Profitability Ratios as of 2026-04-30
Gross Margin
65.0%
Gross profit / revenue
Operating Margin
17.8%
Operating income / revenue
Net Margin
13.2%
Net income / revenue
FCF Margin
14.9%
Free cash flow / revenue
Source tablesView earnings, profitability & valuation tables
Revenue, Net Income, and Free Cash Flow
Annual reported results, using the source statement's recorded USD conversion. Up to 10 reporting periods; missing values are not estimated.
Scroll the table to see every column.
| Period end | Revenue (USD) | Net income (USD) | Free cash flow (USD) |
|---|---|---|---|
| 2017-04-30 | 29,710,000,000 | 4,028,000,000 | 5,626,000,000 |
| 2018-04-30 | 29,953,000,000 | 3,104,000,000 | 3,616,000,000 |
| 2019-04-30 | 30,557,000,000 | 4,631,000,000 | 5,873,000,000 |
| 2020-04-30 | 28,913,000,000 | 4,789,000,000 | 6,021,000,000 |
| 2021-04-30 | 30,117,000,000 | 3,606,000,000 | 4,885,000,000 |
| 2022-04-30 | 31,686,000,000 | 5,039,000,000 | 5,978,000,000 |
| 2023-04-30 | 31,227,000,000 | 3,758,000,000 | 4,580,000,000 |
| 2024-04-30 | 32,364,000,000 | 3,676,000,000 | 5,200,000,000 |
| 2025-04-30 | 33,537,000,000 | 4,662,000,000 | 5,185,000,000 |
| 2026-04-30 | 36,364,000,000 | 4,800,000,000 | 5,426,000,000 |
Published P/E Ratio
Published valuation snapshots retain each observation's earnings basis.
Scroll the table to see every column.
| Period end | P/E (times earnings) | Earnings basis |
|---|---|---|
| 2026-04-30 | 21.68 | Trailing four quarters |
| 2025-04-30 | 23.4 | Trailing four quarters |
| 2024-04-30 | 28.09 | Trailing four quarters |
| 2023-04-30 | 32.23 | Annual net income |
| 2022-04-30 | 27.59 | Annual net income |
Profitability Margins
Matching annual reporting dates. Values are percentages.
Scroll the table to see every column.
| Period end | Gross margin (%) | Operating margin (%) | Net margin (%) | Free cash flow margin (%) |
|---|---|---|---|---|
| 2017-04-30 | 68.72 | 18.12 | 13.56 | 18.94 |
| 2018-04-30 | 69.73 | 22.17 | 10.36 | 12.07 |
| 2019-04-30 | 70.04 | 20.51 | 15.16 | 19.22 |
| 2020-04-30 | 67.41 | 16.57 | 16.56 | 20.82 |
| 2021-04-30 | 65.19 | 14.89 | 11.97 | 16.22 |
| 2022-04-30 | 67.98 | 18.15 | 15.9 | 18.87 |
| 2023-04-30 | 65.67 | 17.56 | 12.03 | 14.67 |
| 2024-04-30 | 65.34 | 15.89 | 11.36 | 16.07 |
| 2025-04-30 | 65.32 | 17.76 | 13.9 | 15.46 |
| 2026-04-30 | 65.02 | 17.78 | 13.2 | 14.92 |
Public data excerpt created by iPulse AI and published by Future Edge Group FZE. Source: eodhd. Snapshot retrieved 2026-09-29.
Use is subject to the iPulse AI Terms of Service and applicable source rights. Missing inputs are not estimated. Full access includes the remaining records, research and interactive tools.
Complete Research Workspace
Unlock the complete Profile & Fundamentals
Sign in to verify your access, or upgrade to the Base plan to open the complete profile & fundamentals and available source data.